Exane BNP Paribas analyst James Picariello initiates coverage on Visteon (NASDAQ:VC) with a Neutral rating.
Predictive Oncology Q3 EPS $(0.05) Up From $(0.08) YoY, Sales $455.83M Up From $313.66K YoY
Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.05) per share. This is a 37.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported $455.83 million in
